|
|
Ardian(R) Demonstrates 2-Year Durability of Blood Pressure Reduction in ... - PR Newswire (press release) |
|
PR Newswire (press release)Both vascular and renal safety were also carefully assessed in the study and reported during the presentation. Renal vascular safety was assessed by imaging ... |
|
|
Research Roundup: Medical Homes Working In Poor Areas, Designing Insurance ... - Medical News Today (press release) |
|
Medical News Today (press release)Journal of the American Society of Nephrology: Racial Composition Of Residential Areas Associates With Access To Pre-ESRD Nephrology Care - Clinical ... |
|
ISN 50 Years live webcast |
|
DOH-NKTI, PIA hold lay forum on renal disease control program - Philippine Information Agency |
|
Philippine Information AgencyREDCOP is the office in-charge of implementing the NKTI's public health projects on the prevention and control of renal and other related diseases. ... |
|
Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for ... - MarketWatch (press release) |
|
MarketWatch (press release)In a subgroup analysis of CSE events in the EMERALD studies in maintenance treatment of anemia in dialysis patients, the frequency of CSE events was ...Piper Jaffray Downgrades Affymax (AFFY) to Underweight; Disappointing Hematide ... StreetInsider.com (subscription)Affymax shares plunge on PhIII cardio issues for Hematide FierceBiotechAffymax' Anemia Drug Meets Goals Of Phase III Trials; Shares Plunge On Safety ... |
|
|
|
|
<< Start < Prev 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 Next > End >>
|
|
Page 1506 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
